SC vs. IV administration of a BCMA-CD3 bispecific antibody for R/R myeloma
Alexander Lesokhin • 4 Dec 2020
Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Keep up to date with all the latest news with our monthly newsletter